LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

Search

Medtronic PLC

Suletud

SektorTervishoid

93.13 3.57

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

89.77

Max

94.27

Põhinäitajad

By Trading Economics

Sissetulek

-237M

1.1B

Müük

635M

8.9B

P/E

Sektori keskmine

25.709

35.473

Aktsiakasum

1.26

Dividenditootlus

3.01

Kasumimarginaal

11.84

Töötajad

95,000

EBITDA

-126M

2.3B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+10.12% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.01%

2.38%

Järgmine tulemuste avaldamine

18. nov 2025

Järgmine dividendimakse kuupäev

17. okt 2025

Järgmine aktsia dividendi kuupäev (ex-date)

26. sept 2025

Turustatistika

By TradingEconomics

Turukapital

-4.1B

119B

Eelmine avamishind

89.56

Eelmine sulgemishind

93.13

Uudiste sentiment

By Acuity

35%

65%

138 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Medtronic PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. aug 2025, 11:39 UTC

Tulu

Medtronic Posts Higher 1Q Revenue, Boosts Outlook as Tariffs Ease

21. mai 2025, 11:38 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

19. aug 2025, 20:33 UTC

Tulu
Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Intel, Home Depot, Palo Alto, Viking Therapeutics, Palantir, Medtronic, and More -- Barrons.com

19. aug 2025, 17:41 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

19. aug 2025, 13:35 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Intel, Medtronic, Home Depot -- WSJ

19. aug 2025, 12:48 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

19. aug 2025, 11:27 UTC

Tulu

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

19. aug 2025, 10:51 UTC

Tulu

Medtronic Sees FY26 Reported Revenue Growth 6.5%-6.8% >MDT

19. aug 2025, 10:50 UTC

Tulu

Medtronic Had Seen FY26 Adjusted EPS $5.50-$5.60 >MDT

19. aug 2025, 10:50 UTC

Tulu

Medtronic Raises FY26 View To Adj EPS $5.60-Adj EPS $5.66 >MDT

19. aug 2025, 10:50 UTC

Tulu

Medtronic Cuts FY26 Potential Tariff Impact View to About $185M From $200M-$350M >MDT

19. aug 2025, 10:49 UTC

Tulu

Medtronic Raises FY26 Adjusted EPS Growth View to About 4.5% From About 4%, Excluding Potential Tariff Impact >MDT

19. aug 2025, 10:48 UTC

Tulu

Medtronic Still Sees FY26 Organic Revenue Up About 5% >MDT

19. aug 2025, 10:45 UTC

Tulu

Medtronic 1Q Medical Surgical Portfolio Rev $2.08B >MDT

19. aug 2025, 10:45 UTC

Tulu

Medtronic 1Q Cardiovascular Portfolio Rev $3.29B >MDT

19. aug 2025, 10:45 UTC

Tulu

Medtronic 1Q Neuroscience Portfolio Rev $2.42B >MDT

19. aug 2025, 10:45 UTC

Tulu

Medtronic 1Q Organic Revenue Up 4.8% >MDT

19. aug 2025, 10:45 UTC

Tulu

Medtronic 1Q EPS 81c >MDT

19. aug 2025, 10:45 UTC

Tulu

Medtronic 1Q Net $1.04B >MDT

19. aug 2025, 10:45 UTC

Tulu

Medtronic 1Q Diabetes Rev $721M >MDT

19. aug 2025, 10:45 UTC

Tulu

Medtronic 1Q Sales $8.58B >MDT

19. aug 2025, 10:45 UTC

Tulu

Medtronic 1Q Adj EPS $1.26 >MDT

19. aug 2025, 09:12 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Intel, Palo Alto, Tegna, Home Depot -- WSJ

12. juuni 2025, 13:01 UTC

Omandamised, ülevõtmised, äriostud

Medtronic Targeting Completion of Planned Separation Within 18 Mos of Initial Announcement >MDT

21. mai 2025, 17:23 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

21. mai 2025, 11:39 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

21. mai 2025, 10:52 UTC

Tulu

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

21. mai 2025, 10:51 UTC

Tulu

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

21. mai 2025, 10:50 UTC

Tulu

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

21. mai 2025, 10:49 UTC

Tulu

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

Võrdlus sarnastega

Hinnamuutus

Medtronic PLC Prognoos

Hinnasiht

By TipRanks

10.12% tõus

12 kuu keskmine prognoos

Keskmine 99 USD  10.12%

Kõrge 110 USD

Madal 78 USD

Põhineb 26 Wall Streeti analüütiku instrumendi Medtronic PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

26 ratings

13

Osta

12

Hoia

1

Müü

Tehniline skoor

By Trading Central

83.26 / 84.875Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

138 / 373 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.